Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcast
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcast
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Original Research

Improved Pregnancy Outcome in Type 1 Diabetic Women With Microalbuminuria or Diabetic Nephropathy

Effect of intensified antihypertensive therapy?

  1. Lene Ringholm Nielsen, MD, PHD12,
  2. Peter Damm, MD, DMSC13 and
  3. Elisabeth R. Mathiesen, MD, DMSC12
  1. 1Center for Pregnant Women with Diabetes, Rigshospitalet, Faculty of Health Sciences, Copenhagen, Denmark
  2. 2Department of Endocrinology, Rigshospitalet, Faculty of Health Sciences, Copenhagen, Denmark
  3. 3Department of Obstetrics, Rigshospitalet, Faculty of Health Sciences, Copenhagen, Denmark
  1. Corresponding author: Lene Ringholm Nielsen, enel{at}dadlnet.dk
Diabetes Care 2009 Jan; 32(1): 38-44. https://doi.org/10.2337/dc08-1526
PreviousNext
  • Article
  • Figures & Tables
  • Suppl Material
  • Info & Metrics
  • PDF
Loading

Effect of intensified antihypertensive therapy?

Abstract

OBJECTIVE—To describe pregnancy outcome in type 1 diabetic women with normoalbuminuria, microalbuminuria, or diabetic nephropathy after implementation of an intensified antihypertensive therapeutic strategy.

RESEARCH DESIGN AND METHODS—Prospective study of 117 pregnant women with type 1 diabetes. Antihypertensive therapy, mainly methyldopa, was given to obtain blood pressure <135/85 mmHg and urinary albumin excretion <300 mg/24 h. Blood pressure and A1C were recorded during pregnancy. The pregnancy outcome was compared with recently published studies of pregnant women with microalbuminuria or diabetic nephropathy.

RESULTS—Antihypertensive therapy was given in 14 of 100 women with normoalbuminuria, 5 of 10 women with microalbuminuria, and all 7 women with diabetic nephropathy. Mean systolic blood pressure during pregnancy was 120 mmHg (range 101–147), 122 mmHg (116–135), and 135 mmHg (111–145) in women with normoalbuminuria, microalbuminuria, and diabetic nephropathy, respectively (P = 0.0095). No differences in mean diastolic blood pressure or A1C were detected between the groups. No women with microalbuminuria developed preeclampsia. The frequency of preterm delivery was 20% in women with normoalbuminuria and microalbuminuria in contrast to 71% in women with diabetic nephropathy (P < 0.01) where the median gestational age was 258 days (220–260). Compared with previous studies using less stringent antihypertensive therapeutic strategy and less strict metabolic control, gestational age was longer and birth weight was larger in our study.

CONCLUSIONS—With intensified antihypertensive therapy and strict metabolic control, comparable pregnancy outcome was seen in type 1 diabetic women with microalbuminuria and normoalbuminuria. Although less severe than in previous studies, diabetic nephropathy was associated with more adverse pregnancy outcome.

Type 1 diabetic women with microalbuminuria or diabetic nephropathy are at particular risk of poor pregnancy outcome (1–6). Diabetic nephropathy is associated with a high risk of gestational hypertension, preeclampsia, and preterm delivery (1–4,6). Likewise, preeclampsia and preterm delivery occur more frequently in type 1 diabetic women with microalbuminuria (3,5).

Outside pregnancy, the importance of antihypertensive therapy with ACE inhibition to reduce the risk of renal complications is well documented in both type 1 diabetic patients with microalbuminuria (7) and diabetic nephropathy (8). To prevent development of hypertension and proteinuria, ACE inhibition has been documented to be effective even in normotensive diabetic women with microalbuminuria (7). However, ACE inhibition in early pregnancy has been associated with congenital malformations (9), while use late in pregnancy may cause fetal renal failure (10). ACE inhibition therefore should be discontinued before conception or as soon as pregnancy is confirmed (9). In diabetic women with microalbuminuria or diabetic nephropathy, the effect of antihypertensive therapy in relation to development and progression of hypertension and proteinuria during pregnancy seems promising when using antihypertensive drugs considered safe during pregnancy. However, this is only sparsely investigated (1,3,5).

A retrospective study suggested that early intervention with antihypertensive therapy reduces the risk of preterm delivery in type 1 diabetic women with diabetic nephropathy (1).

Previously, we found an association between early onset of antihypertensive therapy in pregnant type 1 diabetic women with microalbuminuria and a reduced prevalence of preterm delivery, probably due to a reduced prevalence of preeclampsia (5). Methyldopa was first-choice therapy based on reports of stable utero-placental blood flow, fetal hemodynamics (11,12), and long-term follow-up (13). Given that the prevalence of preterm delivery and preeclampsia was still high (5), we speculated that pregnant type 1 diabetic women with microalbuminuria or diabetic nephropathy would benefit from further intensified antihypertensive therapy in early pregnancy. Therefore, in 2004, we intensified our treatment strategy in early pregnancy in type 1 diabetic women with microalbuminuria or diabetic nephropathy.

In this study, we describe the pregnancy outcome in type 1 diabetic women according to their degree of albuminuria after the implementation of an intensified antihypertensive therapeutic strategy.

RESEARCH DESIGN AND METHODS—

During the study period 1 September 2004 to 31 August 2006, we conducted a prospective study consecutively including all pregnancies in Danish-speaking Caucasian women with pregestational type 1 diabetes (n = 121) referred before 14 completed gestational weeks to the Center for Pregnant Women with Diabetes, Rigshospitalet, which offers a joint service involving only a few experienced obstetricians and endocrinologists. All women were referred from a well-defined geographical area covering 2 million inhabitants in eastern Denmark. Women with a single fetus living beyond 22 completed weeks were included in the present analysis.

Two women with Addison's disease and inflammatory bowel disease, respectively, were excluded to avoid the potential bias of competing disease. If a woman had more than one pregnancy in the study period (n = 2), only the first pregnancy was included. A total of 117 women were included in the study and followed until delivery.

Based on the mean of two measurements of 24-h urinary albumin excretions (UAEs) at inclusion, the women were classified as having normoalbuminuria (UAE <30 mg/24 h), microalbuminuria (30–299 mg/24 h), or diabetic nephropathy (UAE ≥300 mg/24 h) accordingly (3). In women with diabetic nephropathy, UAE was also recorded at 14, 21, 27, and 33 weeks. In the remaining women, further analysis of UAE was performed if proteinuria (≥1+) was present in the absence of nitrites and leukocytes on a urinary dipstick (Uristix, Bayer Diagnostics, Bridgend, U.K.), which was checked routinely at each clinical visit. UAE was analyzed by an enzyme-linked immunosorbent assay (14). In a few cases, when 24-h urine samples were not available, albumin-to-creatinine ratio in a random urine sample was performed. We previously reported high concordance between UAE and albumin-to-creatinine ratio with a sensitivity of 94% and specificity of 100% between the two methods (15).

Blood pressure was measured with a digital blood pressure monitor (A&D Instruments, Abingdon, Oxon, U.K.) in a sitting position after 5–10 min of rest. Preeclampsia in women with normoalbuminuria or microalbuminuria was defined as blood pressure >140/90 mmHg accompanied by proteinuria (≥1+) on a sterile urinary dipstick or ≥300 mg/24 h (proteinuria of 300 mg/24 h approximates UAE of 190 mg/24 h) later than 20 weeks. In women with diabetic nephropathy, the diagnosis was based on the same findings accompanied by a sudden increase of ≥15% in systolic or diastolic blood pressure (3).

Antihypertensive therapy was initiated during pregnancy if blood pressure was ≥135/85 mmHg and/or UAE was ≥300 mg/24 h. When ACE inhibitors were withdrawn during prepregnancy planning or in the first weeks of pregnancy, antihypertensive therapy was initiated unless UAE was normal or very low in the microalbuminuric range, in which case the women were observed without antihypertensive therapy (5). Treatment goals were blood pressure <135/85 mmHg and UAE <300 mg/24 h.

Methyldopa (5,11–13) was first-choice therapy in most cases and, when indicated, labetalol and/or nifedipine (5) were added. If given before pregnancy, furosemide was continued during pregnancy to reduce the risk of rebound fluid retention with increased blood pressure and UAE when discontinuing the drug (16).

The majority of women were treated with a basal-bolus insulin regimen. All women registered their self-monitored plasma glucose (SMPG) readings in diabetes diaries, which were evaluated at each clinical visit. Routine SMPG was recommended at least seven times daily to obtain preprandial SMPG of 4.0–6.0 mmol/l, 90-min postprandial SMPG of 4.0–8.0 mmol/l, and prebedtime SMPG of 6.0–8.0 mmol/l (17).

All women visited our and/or their local diabetes center at 1- or 2-week intervals for diabetes control and blood pressure monitoring. Folic acid supplementation during the first 12 weeks of pregnancy was recommended. Structured preconceptional care was not offered systematically.

At median 8 (range 5–13), 14 (12–16), 21 (20–23), 27 (25–29), and 33 (31–35) weeks, weight, A1C, serum creatinine, insulin dose, and blood pressure were recorded, as was the last recorded value of A1C and blood pressure at ∼36 weeks. Median SMPG was calculated as previously described (17). A1C was assayed at our center by a latex immunoagglutination inhibition method on the same analyzer (DCA 2000, Bayer, England). Normal A1C range outside pregnancy was 4.7–6.3%, in early pregnancy 4.5–5.7%, and in late pregnancy 4.4–5.6% (18). Serum creatinine was assayed on a routine basis.

Diabetic retinopathy was diagnosed with retinal photos at inclusion and at 28 weeks. Obstetrical ultrasound scanning was performed on a routine basis at inclusion; at 14, 21, 27, and 33 weeks; and when indicated.

Gestational age was estimated based on early ultrasound scanning. Labor was routinely induced after 37–40 completed weeks based on an individual evaluation including duration of diabetes, presence of diabetic complications, previous obstetric history, and fetal size aiming at getting as close as possible to full term. Preterm delivery comprised delivery before 37 completed weeks and included spontaneous delivery and delivery based on medical indications, mainly preeclampsia, fetal distress, and large-for-gestational-age infants. Small-for-gestational-age was defined as <10th centile and large-for-gestational-age was defined as >90th centile for gestational age and sex for a Danish standard population (19). Perinatal mortality was defined as fetal death after 22 weeks or neonatal death the first week after delivery.

Selective serotonin reuptake inhibitors were given in four women. Thyroid dysfunction was treated with levothyroxine in 16 and with thiamazole in 2, resulting in normal thyroid function in all 18 women during pregnancy.

From the midwifery consultation at Rigshospitalet, 25 healthy pregnant women matched for parity and age and with uncomplicated pregnancies were recruited in the first part of pregnancy. Blood pressure was recorded at median 14 (range 10–19), 28 (20–29), and 34 (32–38) weeks, and pregnancy outcome was collected from patients’ records.

Mean systolic and diastolic blood pressures were calculated for values at 8, 14, 21, 27, and 33 weeks for diabetic women and for values at 14, 28, and 34 weeks in healthy pregnant women. The research protocol was approved by the regional committees for ethics and science and by the Danish Data Protection Agency.

Statistical analysis

Data are given as median (range) or n (%). Categorical variables were compared by χ2 or Fisher's exact test, as appropriate. Continuous variables were analyzed by one-way ANOVA after logarithmic transformation or by nonparametric tests when appropriate.

After logarithmic transformation, repeated measurements of continuous data were analyzed by a variance component model with the continuous variable as the dependent variable, “week” and “group” (normoalbuminuria, microalbuminuria, or diabetic nephropathy) as discrete covariates, and random woman effect as a measure of each woman's level during pregnancy.

Differences were considered to be statistically significant with a two-sided P value <0.05. All statistical analyses were performed using SAS version 9.1 (SAS Institute, Cary, NC).

RESULTS—

At inclusion in early pregnancy, 100 (85%) diabetic women had normoalbuminuria, 10 (9%) microalbuminuria, and 7 (6%) diabetic nephropathy. Median gestational age at the first visit was 61 days (range 37–94) with no difference between the groups (P = 0.30).

During pregnancy, mean systolic blood pressure was 120 mmHg (101–147), 122 mmHg (116–135), and 135 mmHg (111–145) in women with normoalbuminuria, microalbuminuria, and diabetic nephropathy, respectively (P = 0.0095). Corresponding mean diastolic blood pressure was 72 mmHg (62–86), 75 mmHg (65–87), and 74 mmHg (71–86) (P = 0.26). In women with normoalbuminuria and microalbuminuria, no differences in mean systolic blood pressure (P = 0.42) or mean diastolic blood pressure (P = 0.61) were detected. Mean systolic blood pressure was higher in women with diabetic nephropathy compared with the remaining women (P = 0.016). At inclusion, no differences in systolic (P = 0.09) or diastolic (P = 0.20) blood pressure were detected between women with diabetic nephropathy and the remaining women (Figures A1a and A1b are available in an online appendix at http://dx.doi.org/10.2337/dc08-1526).

During pregnancy, mean systolic blood pressure and mean diastolic blood pressure were higher in 86 normoalbuminuric women not receiving antihypertensive therapy during pregnancy compared with healthy pregnant women (120 mmHg [101–138] vs. 117 mmHg [102–128], P = 0.038; and 72 mmHg [62–82] vs. 70 mmHg [56–78], P = 0.023).

The median UAE among women with diabetic nephropathy was maintained well below 2,000 mg/24 h throughout pregnancy (online appendix Figure A1c). However, in late pregnancy, UAE exceeded 2,000 mg/24 h in three women with diabetic nephropathy who delivered preterm, mainly due to preeclampsia (n = 2).

In women with normoalbuminuria, six (6%) were treated with antihypertensive therapy before and during the entire pregnancy, whereas eight (8%) initiated antihypertensive therapy at median 30 weeks (range 14–36). Four (40%) women with microalbuminuria were on antihypertensive drugs before pregnancy, whereas one microalbuminuric woman initiated treatment at 19 weeks. All women with diabetic nephropathy received antihypertensive therapy during pregnancy, of which four (57%) were on treatment before pregnancy, whereas treatment was initiated at the first or second visit in the remaining three women (Table 1).

Two women with diabetic nephropathy had increased serum creatinine (89 and 95 μmol/l at inclusion, increasing to 101 and 125 μmol/l at 33 weeks, normal nonpregnant range 50–88 μmol/l). Glomerular filtration rate measured before pregnancy was 48 and 56 ml/min, respectively. Two years and one pregnancy later, glomerular filtration rate was 45 and 51 ml/min, respectively. Serum creatinine was within the normal range at inclusion in all other women (Table 1) and remained stable throughout pregnancy in the remaining women with diabetic nephropathy (62 μmol/l [44–74] at 33 weeks, n = 4) and in all women with microalbuminuria (52 μmol/l [39–85] at 33 weeks).

Throughout pregnancy, A1C decreased (online appendix Figure A1d), median SMPG levels remained stable (online appendix Figure A1e), and insulin dose increased (data not shown) with no differences between the three groups.

Early preterm delivery before 34 completed weeks occurred in one woman with diabetic nephropathy due to fetal distress and in one woman with normoalbuminuria who experienced rupture of the membranes at 22 completed weeks and delivered an infant that died within 5 min. An unexplained death occurred a few hours after delivery in a term-born infant of a woman with normoalbuminuria. No major congenital malformations or stillbirths were recorded.

None of the women with microalbuminuria developed preeclampsia, and the frequency of preterm delivery among women with microalbuminuria was equal to that in women with normoalbuminuria (Table 1). In women with diabetic nephropathy, three developed preeclampsia resulting in preterm delivery at 35–36 weeks. Median gestational age was 258 days in offspring of women with diabetic nephropathy. A higher frequency of preeclampsia (P = 0.013) and preterm delivery (P = 0.007) was thus seen in women with diabetic nephropathy compared with the remaining women. Spontaneous preterm labor occurred in three normoalbuminuric women, i.e., in 11% of all preterm deliveries, whereas the remaining preterm deliveries were based on obstetric indications. Birth weight did not differ between infants of women with normoalbuminuria and microalbuminuria but was lower in women with diabetic nephropathy (P = 0.017). Furthermore infants of women with diabetic nephropathy more often were small-for-gestational-age (P < 0.01).

A comparison of blood pressure control and pregnancy outcome with recent studies (published within 10 years) in women with microalbuminuria or diabetic nephropathy is shown in Table 2 and Table 3.

CONCLUSIONS—

In this prospective study of 117 pregnant women with type 1 diabetes, we showed that after early intervention with antihypertensive therapy comparable pregnancy outcome was seen in type 1 diabetic women with microalbuminuria and normoalbuminuria, respectively. Although less severe than in previous studies, diabetic nephropathy was associated with more adverse pregnancy outcomes.

The importance of antihypertensive and renoprotective therapy in nonpregnant type 1 diabetic patients is well established (7,8). However, only a few recent studies have focused on the effect of antihypertensive therapy in pregnant type 1 diabetic women with microalbuminuria (3,5) or diabetic nephropathy (1–3), with each study having limitations due to small numbers of patients (3,5), retrospective design (1,2), or missing information about the antihypertensive therapy strategy (2). Until larger randomized prospective trials might become available, there is a need for clinical studies describing the experience regarding indications for and timing of antihypertensive therapy in pregnant women with type 1 diabetes.

This study supports previous findings that intensified antihypertensive therapy may reduce adverse pregnancy outcomes in women with microalbuminuria (5) or diabetic nephropathy (1,2). In the majority of women with microalbuminuria or diabetic nephropathy receiving antihypertensive therapy during pregnancy, this therapy was indeed initiated before pregnancy. However, three women with diabetic nephropathy did not receive antihypertensive therapy before pregnancy, mainly because of poor compliance. Blood pressure levels within target range (<135/85 mmHg) were obtained in the vast majority of women in all three categories of UAE. The antihypertensive therapy was well tolerated, and side effects were not noted. Compliance was not measured but was estimated to be good.

At our center, we have previously evaluated the effect of antihypertensive therapy in pregnant diabetic women with microalbuminuria (3,5) and gradually over the years intensified our antihypertensive therapy strategy accordingly. The present article describes pregnancy outcomes of three cohorts of unselected type 1 diabetic women with microalbuminuria from the same geographical area treated by the same doctors (P.D., E.R.M.) according to three different antihypertensive therapy strategies. Microalbuminuria was previously associated with a high prevalence of preeclampsia and preterm delivery (3,5). With gradually intensified antihypertensive strategies, a decrease in rates of preeclampsia and preterm delivery was seen (Table 2), resulting in pregnancy outcome comparable with that of women with normoalbuminuria.

With the current antihypertensive strategy, infants of women with diabetic nephropathy were delivered at a notably later gestational age compared with previous studies from our (3) and other (1,2,4,6) centers, which used less intensive antihypertensive strategies. In the current study, birth weight of infants born to women with diabetic nephropathy was substantially higher than in previous studies (1–3) and only two infants were small-for-gestational-age. Nonetheless, the majority of infants of women with diabetic nephropathy were born preterm and were smaller compared with the remaining infants of diabetic mothers. No neonatal deaths were recorded in women with diabetic nephropathy, but because of the low number of women studied, no firm conclusion regarding infrequent pregnancy outcomes can be drawn.

Women with diabetic nephropathy were more prone to develop preeclampsia in agreement with previous studies (1–4,6,20). Hod et al. (21) reported that in eight highly selected type 1 diabetic women with diabetic nephropathy, ACE inhibition before pregnancy offered a prolonged protective renal effect throughout pregnancy with favorable pregnancy outcome. In the current study, however, two of three women with diabetic nephropathy developing superimposed preeclampsia received ACE inhibition before pregnancy.

Serum creatinine was used as an index of renal function as in the study of Dunne et al. (2), who found increasing serum creatinine during pregnancy in women with diabetic nephropathy. In contrast, we found stable serum creatinine in the women with microalbuminuria or diabetic nephropathy if serum creatinine was within normal range in early pregnancy in accordance with Rossing et al. (22), although the numbers were too small for solid conclusions. Women with diabetic nephropathy were followed with frequent determinations of UAE, whereas in women with normoalbuminuria or microalbuminuria, further analysis of UAE was only performed systematically when dipstick analysis was ≥1+ during pregnancy. Even in the two women with elevated serum creatinine during pregnancy, the annual change in glomerular filtration rate of 1.5–3 ml/min was not different from what could be expected in the most optimally treated women with diabetic nephropathy (22).

Antihypertensive therapy with up to four drugs was indicated in the women with diabetic nephropathy. Nonetheless, their systolic blood pressure was slightly higher compared with the remaining pregnant diabetic women. This may reflect long-term hemodynamic alterations and necessitate an even more intensive antihypertensive therapy strategy before and during pregnancy (1). Blood pressure levels were within target range in the vast majority of women with microalbuminuria. Furthermore, in all women with microalbuminuria and in the majority of women with diabetic nephropathy, median UAE was maintained below 2,000 mg/24 h, the limit for nephrotic proteinuria.

Even in normoalbuminuric diabetic women not receiving antihypertensive therapy during pregnancy, blood pressure was higher compared with the healthy pregnant women as previously described (23). This may be associated with increased activity of the renin-angiotensin system in type 1 diabetes, which has previously been demonstrated in pregnant (L.R.N., U. Pedersen-Bjergaard, B. Thorsteinsson, F. Boomsma, P.D., E.R.M., unpublished data) and nonpregnant (24) patients with type 1 diabetes.

When compared with previous studies at our center (3,5), improved glycemic control was obtained in early pregnancy, which may in part explain the lack of congenital malformations. Notably, no differences in A1C were detected between women with normoalbuminuria, microalbuminuria, or diabetic nephropathy during pregnancy. A combined effect of improved glycemic control and early intensive antihypertensive intervention may explain the improved pregnancy outcome obtained in the majority of women with microalbuminuria and diabetic nephropathy in the current study.

To summarize, early antihypertensive therapy and strict metabolic control in pregnant women with type 1 diabetes and microalbuminuria or diabetic nephropathy was associated with improved pregnancy outcome compared with recent reports from our (3,5) and other (1,2) centers.

View this table:
  • View inline
  • View popup
Table 1—

Clinical data in 117 women with type 1 diabetes according to urinary albumin excretion at inclusion in early pregnancy and in 25 healthy pregnant women

View this table:
  • View inline
  • View popup
Table 2—

Comparison of pregnancy outcomes in studies of pregnant type 1 diabetic women with microalbuminuria covering the same geographical area in Eastern Denmark

View this table:
  • View inline
  • View popup
Table 3—

Comparison of pregnancy outcomes in studies of type 1 diabetic women with diabetic nephropathy receiving antihypertensive therapy during pregnancy

Acknowledgments

The study was supported by unrestricted grants from The Danish Diabetes Association and Novo Nordisk A/S, Bagsværd, Denmark. L.R.N. was supported by a fellowship from the Faculty of Health Sciences, Rigshospitalet, Copenhagen, Denmark. No other potential conflicts of interest relevant to this article were reported.

We are indebted to nurses E. Stage and C. Barfred and laboratory technicians K.M. Larsen and M. Wahl for careful handling of the patients and the data.

Footnotes

  • Published ahead of print at http://care.diabetesjournals.org on 22 October 2008.

    Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

    The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

    • Accepted October 10, 2008.
    • Received August 19, 2008.
  • DIABETES CARE

References

  1. ↵
    Carr DB, Koontz GL, Gardella C, Holing EV, Brateng DA, Brown ZA, Easterling TR: Diabetic nephropathy in pregnancy: suboptimal hypertensive control associated with preterm delivery. Am J Hypertens 19: 513–519, 2006
    OpenUrlAbstract/FREE Full Text
  2. ↵
    Dunne FP, Chowdhury TA, Hartland A, Smith T, Brydon PA, McConkey C, Nicholson HO: Pregnancy outcome in women with insulin-dependent diabetes mellitus complicated by nephropathy. QJM 92:451–454, 1999
    OpenUrlAbstract/FREE Full Text
  3. ↵
    Ekbom P, Damm P, Feldt-Rasmussen B, Feldt-Rasmussen U, Molvig J, Mathiesen ER: Pregnancy outcome in type 1 diabetic women with microalbuminuria. Diabetes Care 24:1739–1744, 2001
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Kimmerle R, Zass RP, Cupisti S, Somville T, Bender R, Pawlowski B, Berger M: Pregnancies in women with diabetic nephropathy: long-term outcome for mother and child. Diabetologia 38:227–235, 1995
    OpenUrlCrossRefPubMed
  5. ↵
    Nielsen LR, Muller C, Damm P, Mathiesen ER: Reduced prevalence of early preterm delivery in women with type 1 diabetes and microalbuminuria: possible effect of early antihypertensive treatment during pregnancy. Diabet Med 23:426–431, 2006
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    Reece EA, Coustan DR, Hayslett JP, Holford T, Coulehan J, O'Connor TZ, Hobbins JC: Diabetic nephropathy: pregnancy performance and fetomaternal outcome. Am J Obstet Gynecol 159:56–66, 1988
    OpenUrlCrossRefPubMed
  7. ↵
    Mathiesen ER, Hommel E, Hansen HP, Smidt UM, Parving HH: Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria. BMJ 319:24–25, 1999
    OpenUrlFREE Full Text
  8. ↵
    Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy: the Collaborative Study Group. N Engl J Med 329:1456–1462, 1993
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    Cooper WO, Hernandez-Diaz S, Arbogast PG, Dudley JA, Dyer S, Gideon PS, Hall K, Ray WA: Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 354:2443–2451, 2006
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    Shotan A, Widerhorn J, Hurst A, Elkayam U: Risks of angiotensin-converting enzyme inhibition during pregnancy: experimental and clinical evidence, potential mechanisms, and recommendations for use. Am J Med 96:451–456, 1994
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    Montan S, Anandakumar C, Arulkumaran S, Ingemarsson I, Ratnam SS: Effects of methyldopa on uteroplacental and fetal hemodynamics in pregnancy- induced hypertension. Am J Obstet Gynecol 168:152–156, 1993
    OpenUrlPubMedWeb of Science
  12. ↵
    Montan S, Anandakumar C, Arulkumaran S, Ingemarsson I, Ratnam S: Randomised controlled trial of methyldopa and isradipine in preeclampsia: effects on uteroplacental and fetal hemodynamics. J Perinat Med 24:177–184, 1996
    OpenUrlPubMedWeb of Science
  13. ↵
    Cockburn J, Moar VA, Ounsted M, Redman CW: Final report of study on hypertension during pregnancy: the effects of specific treatment on the growth and development of the children. Lancet 1:647–649, 1982
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    Feldt-Rasmussen B, Dinesen B, Deckert M: Enzyme immunoassay: an improved determination of urinary albumin in diabetics with incipient nephropathy. Scand J Clin Lab Invest 45:539–544, 1985
    OpenUrlPubMedWeb of Science
  15. ↵
    Justesen TI, Petersen JL, Ekbom P, Damm P, Mathiesen ER: Albumin-to-creatinine ratio in random urine samples might replace 24-h urine collections in screening for micro- and macroalbuminuria in pregnant woman with type 1 diabetes. Diabetes Care 29:924–925, 2006
    OpenUrlFREE Full Text
  16. ↵
    National Institute of Health Publication no. 00-3029. National High Blood Pressure Education Program. Available at: http://www.nhlbi.nih-gov/health/prof/heart/hbp/hbp-preg.htm. 2000
  17. ↵
    Nielsen LR, Pedersen-Bjergaard U, Thorsteinsson B, Johansen M, Damm P, Mathiesen ER: Hypoglycemia in pregnant women with type 1 diabetes: predictors and role of metabolic control. Diabetes Care 31:9–14, 2008
    OpenUrlAbstract/FREE Full Text
  18. ↵
    Nielsen LR, Ekbom P, Damm P, Glumer C, Frandsen MM, Jensen DM, Mathiesen ER: HbA1c levels are significantly lower in early and late pregnancy. Diabetes Care 27:1200–1201, 2004
    OpenUrlFREE Full Text
  19. ↵
    Marsal K, Persson PH, Larsen T, Lilja H, Selbing A, Sultan B: Intrauterine growth curves based on ultrasonically estimated foetal weights. Acta Paediatr 85:843–848, 1996
    OpenUrlCrossRefPubMedWeb of Science
  20. ↵
    Lauszus FF, Rasmussen OW, Lousen T, Klebe TM, Klebe JG: Ambulatory blood pressure as predictor of preeclampsia in diabetic pregnancies with respect to urinary albumin excretion rate and glycemic regulation. Acta Obstet Gynecol Scand 80:1096–1103, 2001
    OpenUrlPubMed
  21. ↵
    Hod M, van Dijk DJ, Karp M, Weintraub N, Rabinerson D, Bar J, Peled Y, Erman A, Boner G, Ovadia J: Diabetic nephropathy and pregnancy: the effect of ACE inhibitors prior to pregnancy on fetomaternal outcome. Nephrol Dial Transplant 10:2328–2333, 1995
    OpenUrlAbstract/FREE Full Text
  22. ↵
    Rossing K, Jacobsen P, Hommel E, Mathiesen E, Svenningsen A, Rossing P, Parving HH: Pregnancy and progression of diabetic nephropathy. Diabetologia 45:36–41, 2002
    OpenUrlCrossRefPubMed
  23. ↵
    Napoli A, Sabbatini A, Di BN, Marceca M, Colatrella A, Fallucca F: Twenty-four-hour blood pressure monitoring in normoalbuminuric normotensive type 1 diabetic women during pregnancy. J Diabetes Complications 17:292–296, 2003
    OpenUrlPubMed
  24. ↵
    Toop MJ, Dallinger KJ, Jennings PE, Barnett AH: Angiotensin-converting enzyme (ACE): relationship to insulin-dependent diabetes and microangiopathy. Diabet Med 3:455–457, 1986
    OpenUrlPubMedWeb of Science
View Abstract
PreviousNext
Back to top
Diabetes Care: 32 (1)

In this Issue

January 2009, 32(1)
  • Table of Contents
  • About the Cover
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Improved Pregnancy Outcome in Type 1 Diabetic Women With Microalbuminuria or Diabetic Nephropathy
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
Citation Tools
Improved Pregnancy Outcome in Type 1 Diabetic Women With Microalbuminuria or Diabetic Nephropathy
Lene Ringholm Nielsen, Peter Damm, Elisabeth R. Mathiesen
Diabetes Care Jan 2009, 32 (1) 38-44; DOI: 10.2337/dc08-1526

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Improved Pregnancy Outcome in Type 1 Diabetic Women With Microalbuminuria or Diabetic Nephropathy
Lene Ringholm Nielsen, Peter Damm, Elisabeth R. Mathiesen
Diabetes Care Jan 2009, 32 (1) 38-44; DOI: 10.2337/dc08-1526
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • RESEARCH DESIGN AND METHODS—
    • RESULTS—
    • CONCLUSIONS—
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Tables
  • Suppl Material
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

Original Research

  • Superior Long-Term Survival for Simultaneous Pancreas–Kidney Transplantation as Renal Replacement Therapy: 30-Year Follow-up of a Nationwide Cohort
  • Sex Difference in Effects of Low-Dose Aspirin on Prevention of Dementia in Patients With Type 2 Diabetes: A Long-term Follow-up Study of a Randomized Clinical Trial
  • Glucose and Counterregulatory Responses to Exercise in Adults With Type 1 Diabetes and Impaired Awareness of Hypoglycemia Using Closed-Loop Insulin Delivery: A Randomized Crossover Study
Show more Original Research

Clinical Care/Education/Nutrition/Psychosocial Research

  • Reduction in Glycated Hemoglobin and Daily Insulin Dose Alongside Circadian Clock Upregulation in Patients With Type 2 Diabetes Consuming a Three-Meal Diet: A Randomized Clinical Trial
  • Changes in Consumption of Sugary Beverages and Artificially Sweetened Beverages and Subsequent Risk of Type 2 Diabetes: Results From Three Large Prospective U.S. Cohorts of Women and Men
  • Genetic Prediction of Serum 25-Hydroxyvitamin D, Calcium, and Parathyroid Hormone Levels in Relation to Development of Type 2 Diabetes: A Mendelian Randomization Study
Show more Clinical Care/Education/Nutrition/Psychosocial Research

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • BMJ Open - Diabetes Research & Care
  • Standards of Medical Care in Diabetes
  • Scientific Sessions Abstracts
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2019 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.